Challenges and progress in adverse event ascertainment and reporting in clinical trials

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 2030-2032

  Lassere, Marissa N D ^a,c   Johnson, Kent R ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

Author keywords

Adverse event reporting; Patient questionnaires; Randomized controlled trials

Indexed keywords

ANTIRHEUMATIC AGENT;

CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RHEUMATOLOGY COMMON TOXICITY CRITERIA; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SELF REPORT; SHORT FORM 36; SIDE EFFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; HUMANS; PATIENTS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS; RHEUMATOLOGY;

EID: 26444607903     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. Doing more good than harm. The evaluation of health care interventions. In: Warren K, Mosteller F, editors. Conference proceedings. New York, NY, March 22-25, 1993. Ann NY Acad Sci 1993;703:1b-341b.
2. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
3. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: a user's manual. Boston: The Health Institute, New England Medical Center; 1994.
4. Fries JF. The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index. Control Clin Trials 1991;12 Suppl:106S-17S.
5. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for the evaluation of health care programs. Health Serv Res 1972;7:118-33.
6. Torrance GW. Utility approach to measuring health related quality of life. J Chronic Dis 1987;40:593-603.
7. Friedman L, Furberg C, DeMets D. Fundamentals of clinical trials. 3rd ed. New York: Springer; 1998.
8. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.
9. National Cancer Institute. Cancer Therapy Evaluation Program. Common toxicity criteria version 2.0 manual. Bethesda: National Cancer Institute; 1999.
10. Perrone F, Maione P, De Maio E, et al. Survey of modalities of assessing and reporting toxicity in non-comparative prospective studies of chemotherapy in breast cancer. J Clin Oncol 2002;20:52-7.
11. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 2004;22:19-22.
12. Trotti A. The evolution of toxicity criteria and reporting standards. Semin Radiat Oncol 2002;12 Suppl:1-3.
13. Gwede C, Johnson D, Daniels S, et al. Assessment of toxicity in cooperative oncology trials: The long and short of it. J Oncol Manag 2002;11:15-21.
14. Bentzen SM. Towards evidence based radiation oncology: Improving the design, analysis and reporting of clinical outcome studies in radiotherapy. Radiother Oncol 1998;46:5-18.
15. Ioannidis JP, Contopoulos-Ioannidis DG. Reporting of safety data from randomised trials. Lancet 1998;352:1752-3.
16. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. JAMA 2001;285:437-43.
17. Ioannidis JP, Lau J. Improving safety reporting from randomised trials. Drug Safety 2002;25:77-84.
18. Brooks PM, Day RO. Toxicity of antirheumatic drugs. Toxicity workgroup leaders. J Rheumatol 1995;22:998-9.
19. Day RO, Quinn DI, Conaghan PG, Tett SE. Adverse drug reactions and their measurement in the rheumatic diseases. J Rheumatol 1995;22:983-8.
20. Peloso PM, Wright JG, Bombardier C. A critical appraisal of toxicity indexes in rheumatology. J Rheumatol 1995;22:989-94.
21. Gazarian M, Tugwell P, Boers M, et al. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT drug toxicity working party. Outcome measures in rheumatology. J Rheumatol;1999:26:207-9.
22. Fries JF, Spitz PW, Williams CA, Bloch DA, Singh G, Hubert HB. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-30.
23. Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33:9-18.
24. Duffy CM, Arsenault L, Watanabe Duffy KN, Paquin JD, Strawczynski H. The Juvenile Arthritis Quality of Life Questionnaire - development of a new responsive index for juvenile rheumatoid arthritis and juvenile spondyloarthritides. J Rheumatol 1997;24:738-46.
25. Welch V, Singh G, Strand V, et al. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index. J Rheumatol 2001;28:1188-91.
26. Boers M, Brooks P, Strand CV, Tugwell P. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
27. National Cancer Institute. National Cancer Institute common terminology criteria for adverse events (CTCAE), version 3. [Internet.] Accessed June 5, 2005. Available from: http://www.fda.gov/cder/cancer/toxicityframe.htm
28. Woodworth TG, Furst DE, Strand V, et al. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT toxicity working group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies. J Rheumatol 2001;28:1163-9.
29. Lassere MN, van Santen S, Carlton K, et al. Patient self-report and investigator report adverse event instruments. A generic measure of drug safety and tolerability. J Rheumatol 2005;32:2033-6.
30. Lassere MN, Johnson K, Boers M, et al. Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 Drug Safety Module Update. J Rheumatol 2005;32:2037-41.